Patents by Inventor Frank J. Schoenen
Frank J. Schoenen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11241436Abstract: The invention provides a compound of formula (I): wherein R1, R2, R3, and R4 are as defined herein, ginsenoside Rg2 of structure (II): or a combination thereof, for use in treating or preventing a condition responsive to the induction of autophagy in a brain of a mammal in need thereof.Type: GrantFiled: January 25, 2018Date of Patent: February 8, 2022Assignees: Northwestern University, The United States of Americans represented by the Secretary, Department of Health and Human Services, University of KansasInventors: Congcong He, Sui Huang, Chen Wang, Altea Rocchi, Juan Jose Marugan, Marc Ferrer, Samarjit Patnaik, Yuchi Chen, Kevin Frankowski, Frank J. Schoenen
-
Publication number: 20200009146Abstract: The invention provides a compound of formula (I): wherein R1, R2, R3, and R4 are as defined herein, ginsenoside Rg2 of structure (II): or a combination thereof, for use in treating or preventing a condition responsive to the induction of autophagy in a brain of a mammal in need thereof.Type: ApplicationFiled: January 25, 2018Publication date: January 9, 2020Applicants: Northwestern University, The United States of America, as Represented by the Secretary, Department of Health & Human Services, University of KansasInventors: Congcong HE, Sui HUANG, Chen WANG, Altea ROCCHI, Juan Jose MARUGAN, Marc FERRER, Samarjit PATNAIK, Yuchi CHEN, Kevin FRANKOWSKI, Frank J. SCHOENEN
-
Patent number: 10301314Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.Type: GrantFiled: May 26, 2017Date of Patent: May 28, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Kansas, Northwestern UniversityInventors: Kevin Frankowski, Samarjit Patnaik, Sui Huang, Juan Jose Marugan, John Norton, Frank J. Schoenen, Noel Terrence Southall, Steven Titus, Wei Zheng, Chen Wang
-
Patent number: 10202367Abstract: Disclosed are compounds of formula (I), formula (II), and formula (III): wherein Ar, R1, A, and X are as defined in the specification. These compounds are antiviral agents and are contemplated for use in the treatment of viral infections, for example, hepatitis C. These compounds are also contemplated for use in treating or preventing cancers.Type: GrantFiled: June 12, 2015Date of Patent: February 12, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of KansasInventors: Tsanyang Liang, Zongyi Hu, Juan Jose Marugan, Noel Terrence Southall, Shanshan He, Xin Hu, Jingbo Xiao, Marc Ferrer, Wei Zheng, Kevin J. Frankowski, Frank J. Schoenen, Kelin Li
-
Patent number: 10124377Abstract: A laboratory fume hood system for cooling at least one laboratory device located in an interior work area comprises a heat exchanger system having a heat exchanger in thermal communication with a primary fluid loop containing chilled fluid and a secondary fluid loop containing a cooling fluid which is in thermal communication the laboratory device. The primary fluid loop is located behind the fume hood wall and not in the interior work area.Type: GrantFiled: October 10, 2016Date of Patent: November 13, 2018Assignee: UNIVERSITY OF KANSASInventors: George S. Wilson, William Scott Jeffress, Frank J. Schoenen
-
Publication number: 20170260192Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.Type: ApplicationFiled: May 26, 2017Publication date: September 14, 2017Applicants: The United States of America, as represented by the Secretary, Dept of Health and Human Services, University of Kansas, Northwestern UniversityInventors: Kevin Frankowski, Samarjit Patnaik, Sui Huang, Juan Jose Marugan, John Norton, Frank J. Schoenen, Noel Terrence Southall, Steven Titus, Wei Zheng
-
Patent number: 9663521Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.Type: GrantFiled: December 17, 2012Date of Patent: May 30, 2017Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Kansas, Northwestern UniversityInventors: Kevin Frankowski, Samarjit Patnaik, Sui Huang, Juan Jose Marugan, John Norton, Frank J. Schoenen, Noel Terrence Southall, Steven Titus, Wei Zheng
-
Publication number: 20170114053Abstract: Disclosed are compounds of formula (I), formula (II), and formula (III): wherein Ar, R1, A, and X are as defined in the specification. These compounds are antiviral agents and are contemplated for use in the treatment of viral infections, for example, hepatitis C. These compounds are also contemplated for use in treating or preventing cancers.Type: ApplicationFiled: June 12, 2015Publication date: April 27, 2017Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, University of KansasInventors: Tsanyang Liang, Zongyi Hu, Juan Jose Marugan, Noel Terrence Southall, Shanshan He, Xin Hu, Jingbo Xiao, Marc Ferrer, Wei Zheng, Kevin J. Frankowski, Frank J. Schoenen, Kelin Li
-
Publication number: 20170021399Abstract: A laboratory fume hood system for cooling at least one laboratory device located in an interior work area comprises a heat exchanger system having a heat exchanger in thermal communication with a primary fluid loop containing chilled fluid and a secondary fluid loop containing a cooling fluid which is in thermal communication the laboratory device. The primary fluid loop is located behind the fume hood wall and not in the interior work area.Type: ApplicationFiled: October 10, 2016Publication date: January 26, 2017Applicant: UNIVERSITY OF KANSASInventors: GEORGE S. WILSON, WILLIAM SCOTT JEFFRESS, FRANK J. SCHOENEN
-
Patent number: 9463495Abstract: A laboratory fume hood system for cooling at least one laboratory device located in an interior work area comprises a heat exchanger system having a heat exchanger in thermal communication with a primary fluid loop containing chilled fluid and a secondary fluid loop containing a cooling fluid which is in thermal communication the laboratory device. The primary fluid loop is located behind the fume hood wall and not in the interior work area.Type: GrantFiled: August 14, 2013Date of Patent: October 11, 2016Assignee: UNIVERSITY OF KANSASInventors: George S. Wilson, William Scott Jeffress, Frank J. Schoenen
-
Patent number: 9289760Abstract: An apparatus for providing coolant fluid to a device, the apparatus includes a heat exchanger having a hot side and a cold side. The cold side is in fluid communication with a chilled fluid supply and adapted to receive a first fluid from the chilled fluid supply in a first inlet and return the first fluid from the cold side to the chilled fluid supply. The cold side and the chilled fluid supply form a first fluid circuit. The apparatus further includes a second fluid circuit in fluid communication with the hot side, means for introducing a second fluid within the second fluid circuit and integral thereto, a pump integral to the second fluid circuit and adapted to transmit a second fluid within the second fluid circuit and means for controlling a rate of flow of the second fluid within the second fluid circuit. The device is within the second fluid circuit and the means for controlling the rate of flow operates in the absence of internal recirculation.Type: GrantFiled: February 26, 2009Date of Patent: March 22, 2016Assignees: Cannon Design, Inc., University of KansasInventors: Gerald G. Williams, Andrew D. Hager, George S. Wilson, William Scott Jeffress, Frank J. Schoenen
-
Publication number: 20140323438Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.Type: ApplicationFiled: December 17, 2012Publication date: October 30, 2014Inventors: Kevin Frankowski, Samarjit Patnaik, Sui Huang, Juan Jose Marugan, John Norton, Frank J. Schoenen, Noel Terrence Southall, Steven Titus, Wei Zheng
-
Patent number: 8865708Abstract: Compounds of Formulas I-XLIII are identified as direct inhibitors of p97 ATPase or of the degradation of a p97-dependent ubiquitin-proteasome system (UPS) substrate. Methods and compositions are disclosed for inhibiting p97 ATPase and the degradation of a p97-dependent UPS substrate, and for identifying inhibitors thereof.Type: GrantFiled: May 6, 2011Date of Patent: October 21, 2014Assignees: California Institute of Technology, The University of Kansas, Cleave Biosciences, Inc.Inventors: Raymond J. Deshaies, Tsui-Fen Chou, Frank J. Schoenen, Kelin Li, Kevin J. Frankowski, Jeffrey Aube, Samuel W. Gerritz, Han-Jie Zhou
-
Publication number: 20130331018Abstract: A laboratory fume hood system for cooling at least one laboratory device located in an interior work area comprises a heat exchanger system having a heat exchanger in thermal communication with a primary fluid loop containing chilled fluid and a secondary fluid loop containing a cooling fluid which is in thermal communication the laboratory device. The primary fluid loop is located behind the fume hood wall and not in the interior work area.Type: ApplicationFiled: August 14, 2013Publication date: December 12, 2013Applicant: University Of KansasInventors: GEORGE S. WILSON, WILLIAM SCOTT JEFFRESS, FRANK J. SCHOENEN
-
Patent number: 8362072Abstract: A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof; and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1.Type: GrantFiled: June 18, 2012Date of Patent: January 29, 2013Assignee: University of KansasInventors: Roy A. Jensen, Lisa M. Harlan-Williams, Frank J. Schoenen, Jeffrey Aube, Gerald H. Lushington
-
Publication number: 20120259005Abstract: A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof; and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1.Type: ApplicationFiled: June 18, 2012Publication date: October 11, 2012Applicant: University of KansasInventors: Roy A. Jensen, Lisa M. Harlan-Williams, Frank J. Schoenen, Jeffrey Aube, Gerald H. Lushington
-
Publication number: 20110288082Abstract: Compounds of Formulas I-XLIII are identified as direct inhibitors of p97 ATPase or of the degradation of a p97-dependent ubiquitin-proteasome system (UPS) substrate.Type: ApplicationFiled: May 6, 2011Publication date: November 24, 2011Inventors: Raymond J. Deshaies, Tsui-Fen Chou, Frank J. Schoenen, Kelin Li, Kevin J. Frankowski, Jeffrey Aube, Samuel W. Gerritz, Han-Jie Zhou
-
Publication number: 20090264384Abstract: Benzimidazole, indole and benzolactam boronic acid compounds, analogs thereof, and pharmaceutical formulations are described, along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-?) in a subject in need thereof.Type: ApplicationFiled: November 10, 2008Publication date: October 22, 2009Applicant: Nuada, Inc.Inventors: John R. Didsbury, Tatyana Dyakonov, Simon N. Haydar, Michael L. Jones, Francine F. Li, Christopher J. Markworth, Jessy Matthew, Frank J. Schoenen, Jan J. Scicinski, David Middlemiss, James F. Burns, Leonard A. Cabana, Glenn C. Collupy, David N. Vanvliet
-
Publication number: 20090170842Abstract: A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof, and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1.Type: ApplicationFiled: November 13, 2008Publication date: July 2, 2009Applicant: University of KansasInventors: Roy A. Jensen, Lisa M. Harlan-Williams, Frank J. Schoenen, Jeffrey Aube, Gerald H. Lushington
-
Patent number: D821554Type: GrantFiled: September 30, 2016Date of Patent: June 26, 2018Assignee: The University of KansasInventors: George S. Wilson, William Scott Jeffress, Frank J. Schoenen